Search hospitals > Illinois > Geneva
Northwestern Medicine Cancer Center Delnor
Claim this profileGeneva, Illinois 60134
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Adenocarcinoma
Conducts research for Recurrence
Conducts research for Lung Cancer
174 reported clinical trials
45 medical researchers
Summary
Northwestern Medicine Cancer Center Delnor is a medical facility located in Geneva, Illinois. This center is recognized for care of Cancer, Breast Cancer, Adenocarcinoma, Recurrence, Lung Cancer and other specialties. Northwestern Medicine Cancer Center Delnor is involved with conducting 174 clinical trials across 358 conditions. There are 45 research doctors associated with this hospital, such as Aparna Kalyan, Sunandana Chandra, Devalingam Mahalingam, MBBChBAO, and Jochen H. Lorch, M.D..Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
Top PIs
Aparna KalyanNorthwestern University1 year of reported clinical research
Expert in Cancer
Studies Bile Duct Cancer
20 reported clinical trials
39 drugs studied
Sunandana ChandraNorthwestern University1 year of reported clinical research
Expert in Melanoma
Expert in Skin Cancer
22 reported clinical trials
31 drugs studied
Devalingam Mahalingam, MBBChBAONorthwestern University5 years of reported clinical research
Studies Solid Tumors
Studies Tumors
16 reported clinical trials
51 drugs studied
Jochen H. Lorch, M.D.Northwestern University3 years of reported clinical research
Studies Cancer
Studies Oral Squamous Cell Carcinoma
15 reported clinical trials
25 drugs studied
Clinical Trials running at Northwestern Medicine Cancer Center Delnor
Breast Cancer
Esophageal Adenocarcinoma
Cancer
Prostate Cancer
Gastroesophageal Junction Adenocarcinoma
Esophageal Carcinoma
Lung Cancer
Non-Small Cell Lung Cancer
Renal Cell Carcinoma
Diffuse Large B-Cell Lymphoma
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Northwestern Medicine Cancer Center Delnor?
Northwestern Medicine Cancer Center Delnor is a medical facility located in Geneva, Illinois. This center is recognized for care of Cancer, Breast Cancer, Adenocarcinoma, Recurrence, Lung Cancer and other specialties. Northwestern Medicine Cancer Center Delnor is involved with conducting 174 clinical trials across 358 conditions. There are 45 research doctors associated with this hospital, such as Aparna Kalyan, Sunandana Chandra, Devalingam Mahalingam, MBBChBAO, and Jochen H. Lorch, M.D..